Literature DB >> 17260953

Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains.

Brian O'Nuallain1, Amy Allen, Stephen J Kennel, Deborah T Weiss, Alan Solomon, Jonathan S Wall.   

Abstract

Amyloid fibrils and partially unfolded intermediates may be distinguished serologically from native amyloidogenic precursor proteins or peptides. In this regard, we had previously reported that the IgG1 mAb 11-1F4, generated by immunizing mice with a thermally denatured variable region fragment of the human Igkappa4 Bence Jones protein Len, reacted specifically with light chain (LC) fibrils, irrespective of kappa or lambda isotype but, notably, did not with native molecules (Hrncic, R. et al. (2000) Am. J. Pathol. 157, 1239-1246). To elucidate the molecular basis of this specificity, we have used a europium-linked fluorescent immunoassay, where it was demonstrated through epitope mapping that mAb 11-1F4 recognizes a conformational determinant contained within the first (N-terminal) 18 amino acids of misfolded LCs. The nature of this epitope was evidenced in competition studies where the peptide Len (1-18), but not the intact protein or other LCs, inhibited the binding of the antibody to fibrils. This unique reactivity was dependent on the structural integrity of this portion of the molecule, particularly the presence of a highly conserved prolyl residue at position 8. On the basis of our experimental data, we posit that the mAb 11-1F4 binding site found on partially denatured and fibrillar LCs involves an inducible N-terminal main chain reversal that results in the formation of a proline anchored beta-turn. Our delineation of this LC fibril-associated epitope provides the rationale for the design of novel amyloid-reactive antibodies with diagnostic and therapeutic potential for patients with LC-associated and other forms of amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17260953      PMCID: PMC1832162          DOI: 10.1021/bi0616605

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  46 in total

Review 1.  Immunoassays with time-resolved fluorescence spectroscopy: principles and applications.

Authors:  E P Diamandis
Journal:  Clin Biochem       Date:  1988-06       Impact factor: 3.281

2.  Two cis-prolines in the Bence-Jones protein Rei and the cis-pro-bend.

Authors:  R Huber; W Steigemann
Journal:  FEBS Lett       Date:  1974-11-15       Impact factor: 4.124

3.  Antisera specific for human amyloid reactive with conformational antigens.

Authors:  E C Franklin; D Zucker-Franklin
Journal:  Proc Soc Exp Biol Med       Date:  1972-06

4.  Light chains of human immunoglobulins.

Authors:  A Solomon
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

Review 5.  Turns in peptides and proteins.

Authors:  G D Rose; L M Gierasch; J A Smith
Journal:  Adv Protein Chem       Date:  1985

6.  [The primary structure of a monoclonal immunoglobulin L-chain of kappa-type, subgroup IV (Bence-Jones protein Len.). A new subgroup of the kappa-type L-chain].

Authors:  M Schneider; N Hilschmann
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1974-09

7.  Epitope scanning reveals gain and loss of strain specific antibody binding epitopes associated with the conversion of normal cellular prion to scrapie prion.

Authors:  Tao Pan; Ruliang Li; Shin-Cheng Kang; Boon-Seng Wong; Thomas Wisniewski; Man-Sun Sy
Journal:  J Neurochem       Date:  2004-09       Impact factor: 5.372

8.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

9.  The characterization of soluble amyloid prepared in water.

Authors:  M Pras; M Schubert; D Zucker-Franklin; A Rimon; E C Franklin
Journal:  J Clin Invest       Date:  1968-04       Impact factor: 14.808

10.  Humoral immune response to fibrillar beta-amyloid peptide.

Authors:  David L Miller; Julia R Currie; Pankaj D Mehta; Anna Potempska; Yu-Wen Hwang; Jerzy Wegiel
Journal:  Biochemistry       Date:  2003-10-14       Impact factor: 3.162

View more
  17 in total

1.  Development and evaluation of agents for targeting visceral amyloid.

Authors:  Jonathan S Wall; Alan Solomon; Stephen J Kennel
Journal:  Tijdschr Nucl Geneeskd       Date:  2011-12

2.  A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.

Authors:  Yona Levites; Brian O'Nuallain; Rama Devudu Puligedda; Tomas Ondrejcak; Sharad P Adekar; Cindy Chen; Pedro E Cruz; Awilda M Rosario; Sallie Macy; Alexandra J Mably; Dominic M Walsh; Ruben Vidal; Alan Solomon; Daniel Brown; Michael J Rowan; Todd E Golde; Scott K Dessain
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

3.  Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains.

Authors:  Sharad P Adekar; Igor Klyubin; Sally Macy; Michael J Rowan; Alan Solomon; Scott K Dessain; Brian O'Nuallain
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

4.  Radioimmunodetection of amyloid deposits in patients with AL amyloidosis.

Authors:  Jonathan S Wall; Stephen J Kennel; Alan C Stuckey; Misty J Long; David W Townsend; Gary T Smith; Karen J Wells; Yitong Fu; Michael G Stabin; Deborah T Weiss; Alan Solomon
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

5.  Macrophage-Mediated Phagocytosis and Dissolution of Amyloid-Like Fibrils in Mice, Monitored by Optical Imaging.

Authors:  Tina Richey; James S Foster; Angela D Williams; Anna B Williams; Alexa Stroh; Sallie Macy; Craig Wooliver; R Eric Heidel; Siva K Varanasi; Elizabeth N Ergen; Dianne J Trent; Stephen A Kania; Stephen J Kennel; Emily B Martin; Jonathan S Wall
Journal:  Am J Pathol       Date:  2019-02-06       Impact factor: 4.307

6.  Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis.

Authors:  Jonathan S Wall; James S Foster; Emily B Martin; Stephen J Kennel
Journal:  Pharm Pat Anal       Date:  2017-08-21

Review 7.  Amyloid formation in light chain amyloidosis.

Authors:  Marina Ramirez-Alvarado
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

8.  Light chain amyloidosis - current findings and future prospects.

Authors:  Elizabeth M Baden; Laura A Sikkink; Marina Ramirez-Alvarado
Journal:  Curr Protein Pept Sci       Date:  2009-10       Impact factor: 3.272

9.  Phage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitope.

Authors:  Brian O'Nuallain; Amy Allen; Demet Ataman; Deborah T Weiss; Alan Solomon; Jonathan S Wall
Journal:  Biochemistry       Date:  2007-10-18       Impact factor: 3.162

10.  Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.

Authors:  Tanya L Poshusta; Laura A Sikkink; Nelson Leung; Raynell J Clark; Angela Dispenzieri; Marina Ramirez-Alvarado
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.